Last updated on August 2019

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lentigo Maligna Melanoma (Head or Neck)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients from both sexes aged over 18 years and operable
  • Presenting with LM of the face, the neck, or the scalp (in case of hairless scalp only) histologically confirmed by biopsy
  • Patients presenting with a primitive lesion, of a surface to 1cm and to 20cm, with the possibility of graft or flap reconstruction
  • LM previously untreated by surgery
  • LM without prior treatment with liquid nitrogen or any other local treatment within 3 months
  • ECOG 2
  • Leucocytes 3,000/mm
  • Neutrophil count 1,500/mm
  • Platelet count 100,000/mm
  • Haemoglobin 9.0g/dL
  • Absence of severe evolutive infection
  • Absence of known HIV infection
  • Absence of corticotherapy and treatment by immunosuppressive agents
  • Absence of excoriation and scarring biopsy prior to application of study treatment
  • Membership to a social security insurance scheme.
  • Negative pregnancy test conducted during the inclusion consultation for non-menopausal women.
  • Effective contraception for patients of childbearing age
  • Signed informed consent

Exclusion Criteria:

  • LM located on the eyelids are excluded, together with LM in anatomic sites other than the face, the neck or the scalp
  • Melanomas other than LM
  • Invasive LM
  • LM with a surface area < to 1cm or > to 20cm
  • LM of which the macroscopic contours cannot be defined
  • Patients who are allergic to imiquimod excipient (eg hydroxybenzoate)
  • Patients with a hypersensitivity to active substances or to any of the excipients of the placebo (for example propyl parahydroxybenzoate)
  • Patients treated by immunosuppressive agents, immunomodulators, cytotoxic agents or corticosteroids (local and systemic) during the 4-week period prior to the selection visit
  • Patients with auto-immune disease (except vitiligo) or transplant patients
  • Cutaneous reconstruction not possible
  • Presence of associated evolutive neoplasia since less than 5 years (with the exception of basal cell carcinoma, Bowen's carcinoma and carcinoma in situ of the cervix)
  • Patient refusing surgery under local or general anaesthesia
  • Pregnant women

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.